The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Investing.com - Novartis (SIX: NOVN )は月曜日、同社のがん治療薬プルビクト (Pluvicto)が前立腺がんの初期段階における後期臨床試験で良好な結果を示したと発表した。

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Reno, Nevada (UroToday.com) -- Novartis announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically ...

Emerging treatments such as bispecific antibodies and radioligand theranostics, including the impact of lutetium-PSMA and updates from the PSMAddition study, showed promise, though practice ...

Novartis’ RLT received US FDA approval for earlier use in mCRPC. Credit: Konektus Photo/Shutterstock. Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified ...

Investing.com -- Novartis (SIX: NOVN) on Monday said that its cancer drug Pluvicto showed positive results in a late-stage ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...